Randomized trial of lamivudine versus entecavir in entecavir‐treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years
James Fung, Ching‐Lung Lai, John Yuen, Charles Cheng, Ringo Wu, Danny Ka‐Ho Wong, Wai‐Kay Seto, Ivan Fan‐Ngai Hung, Man‐Fung Yuen – 14 February 2011 – We aimed to determine the 2‐year outcomes of entecavir followed by lamivudine in patients with undetectable viral load (<12 IU/mL) and normal alanine aminotransferase (ALT) after initial entecavir treatment for at least 6 months. Patients were randomly assigned 1:1 to continue with entecavir or switch to lamivudine. Liver biochemistry and hepatitis B virus (HBV) DNA were determined at weeks 0, 4, 12, 24, 48, 72, and 96.